We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+4.02%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$14.7B
AUM Growth
-$14.5M
Cap. Flow
+$16.2M
Cap. Flow %
0.11%
Top 10 Hldgs %
85.95%
Holding
111
New
8
Increased
15
Reduced
6
Closed
2

Top Buys

Rank Stock Value
1
NVTA
Invitae Corporation
NVTA
+$115M
2
IGMS
IGM Biosciences
IGMS
+$63.5M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$47.4M
4
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$26.6M
5
URGN icon
UroGen Pharma
URGN
+$24.4M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$132M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$113M
3
CPRX
Catalyst Pharmaceutical
CPRX
+$6.49M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$5.15M
5
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$4.91M

Sector Composition

Rank Sector Weight
1 Healthcare 93.54%
2 Financials 0.01%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BCEL
26
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$43.2M 0.29%
3,532,760
– –
GWPH
27
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$42.7M 0.29%
370,845
– –
ZYME icon
28
Zymeworks
ZYME
$1.62B
$42.4M 0.29%
1,708,472
– –
BOLD
29
DELISTED
Audentes Therapeutics, Inc
BOLD
$42.3M 0.29%
1,506,438
– –
INSM icon
30
Insmed
INSM
$22.5B
$39.3M 0.27%
2,229,760
-232,456
-9% -$4.49M
BCRX icon
31
BioCryst Pharmaceuticals
BCRX
$2.44B
$36.5M 0.25%
12,725,472
-1,657,201
-12% -$5.15M
ADPT icon
32
Adaptive Biotechnologies
ADPT
$3.53B
$36M 0.25%
1,165,411
– –
KRYS icon
33
Krystal Biotech
KRYS
$10.7B
$35.9M 0.24%
1,034,674
– –
NGNE icon
34
Neurogene
NGNE
$656M
$32.2M 0.22%
565,284
+18,576
+3% +$1.13M
CBAY
35
DELISTED
Cymabay Therapeutics
CBAY
$29.2M 0.2%
5,707,411
– –
ALLK
36
DELISTED
Allakos
ALLK
$26.7M 0.18%
+339,690
New +$22.4M
KNSA icon
37
Kiniksa Pharmaceuticals
KNSA
$6.21B
$23.8M 0.16%
2,799,577
– –
MRUS
38
DELISTED
Merus
MRUS
$20.7M 0.14%
1,160,014
– –
QURE icon
39
uniQure
QURE
$2.79B
$20.4M 0.14%
517,700
– –
URGN icon
40
UroGen Pharma
URGN
$1.98B
$17.8M 0.12%
+747,751
New +$24.4M
AXSM icon
41
Axsome Therapeutics
AXSM
$11.9B
$15.6M 0.11%
772,286
– –
XNCR icon
42
Xencor
XNCR
$1.46B
$14.4M 0.1%
428,120
– –
AIMT
43
DELISTED
Aimmune Therapeutics
AIMT
$14.1M 0.1%
673,908
– –
PTGX icon
44
Protagonist Therapeutics
PTGX
$8.67B
$14.1M 0.1%
1,174,282
+179,200
+18% +$2.26M
LJPC
45
DELISTED
La Jolla Pharmaceutical Company
LJPC
$13.7M 0.09%
1,559,231
– –
ACGN
46
DELISTED
Aceragen Inc
ACGN
$13.3M 0.09%
271,376
+174
+0.1% +$7.64K
SYRE icon
47
Spyre Therapeutics
SYRE
$8.45B
$13.2M 0.09%
68,544
– –
ALKS icon
48
Alkermes
ALKS
$8.15B
$12.2M 0.08%
625,030
+225,030
+56% +$4.9M
SYRS
49
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$10.1M 0.07%
97,484
– –
SGMO
50
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$9.05M 0.06%
999,823
– –
1
2
3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2019 Portfolio in Review

As of Q3 2019, Baker Bros. Advisors held 111 positions worth $14.7B, down 0.1% from $14.7B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Baker Bros. Advisors's Q3 2019 filing shows 8 new, 15 increased, 6 reduced and 2 closed positions. Its largest new stake was IGM Biosciences: 3,144,000 shares worth $55.8M. The largest sale was Array Biopharma Inc, an estimated $132M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Financials and Technology.

  • Baker Bros. Advisors's largest Q3 2019 buy was IGM Biosciences: 3,144,000 shares worth $55.8M.
  • Baker Bros. Advisors added most to Invitae Corporation in Q3 2019, an estimated $115M increase.
  • Baker Bros. Advisors's biggest Q3 2019 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $113M.
  • Baker Bros. Advisors fully exited Array Biopharma Inc in Q3 2019, selling an estimated $132M.
  • Baker Bros. Advisors's ten largest holdings make up 86% of its $14.7B portfolio in Q3 2019.
  • Baker Bros. Advisors opened 8 new positions and closed 2 in Q3 2019.
  • Baker Bros. Advisors's portfolio value fell 0.1% quarter-over-quarter to $14.7B.

Based on Baker Bros. Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.